Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. US government shutdown: should the FDA go independent?
  2. NHS Long Term Plan: focus on R&D and digital innovation
  3. Pharma companies break 2018 price freeze
  4. Irish authorities demand €1.6bn in back tax from Perrigo
  5. Pharma Technology Focus – Issue 78

Latest Content

The Future of the Pharmaceutical Industry

Ever participated in one of those benchmarking exercises? When a (usually) fresh-faced consultant asks a lot of questions and fills in a spreadsheet comparing what you do with your competitors? Well, beware.

FDA grants breakthrough therapy status to crizanlizumab

Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top